Drug research

Pertuzumab

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Perjeta®

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast CancerNCT05954143	BOLT	Phase 2	Terminated	2024-09-20Actual
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerNCT07102381	Jazz Pharmaceuticals	Phase 2	Recruiting	2028-01-01Estimated

BOLTTerminatedPrimary completion: 2024-09-20 · Actual

Trial details

Jazz PharmaceuticalsRecruitingPrimary completion: 2028-01-01 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.